Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research.
about
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsDipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstructionPrevention of obesity-induced renal injury in male mice by DPP4 inhibition.Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarctionAlogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemDPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese ratThe effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.The pathophysiology of hypertension in patients with obesity.Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.Linagliptin: A thorough Characterization beyond Its Clinical EfficacyNanomedicines for Endothelial Disorders.Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptinDipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsDPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.Tubulointerstitial disease in diabetic nephropathy.Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective propertiesDipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.Renal Effects of DPP-4 Inhibitors: A Focus on MicroalbuminuriaThe gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Is there a role for the incretin system in blood pressure regulation?Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.Linagliptin: from bench to bedside.Linagliptin: an update of its use in patients with type 2 diabetes mellitus.Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.Hibiscus sabdariffa polyphenols prevent palmitate-induced renal epithelial mesenchymal transition by alleviating dipeptidyl peptidase-4-mediated insulin resistance.Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.Do we know the true mechanism of action of the DPP-4 inhibitors?Active subfractions of Abelmoschus esculentus substantially prevent free fatty acid-induced β cell apoptosis via inhibiting dipeptidyl peptidase-4The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout miceSitagliptin ameliorates high glucose-induced cell proliferation and expression of the extracellular matrix in glomerular mesangial cells
P2860
Q26777994-D1D9B914-E57F-438D-952A-255A18E7CD13Q26784211-4CCAAEC8-9F12-4E1D-8DA1-231BC403B22EQ28081569-84C3F326-1A95-4B4E-88D7-E7C35398F886Q28237208-B9B8246F-D148-4F68-A8AE-57618D81A3CAQ33610654-382E6C89-803C-4E55-A6E1-E2B5536E9E18Q33771334-19B4D33F-EE58-413D-AF10-EC1184E79AE2Q33874654-29AF9A71-C35B-42CD-91C1-FB866F4C4358Q34062829-EA02C219-C09A-439B-B8B8-E37DCCCE1529Q34270500-B56D6735-301C-4461-99A0-D0EC5C210450Q34503796-ABBA312A-16CC-4377-ACCE-F25E01857383Q34718326-6A25A7E6-B4FF-4668-98EC-96724473D8C5Q35021492-A31E20F4-BE4E-4812-AE74-47D7C1A0B08CQ35928257-9E88B5DF-6933-4E33-B5D2-F3F7DFAE19DAQ36636639-317FB8CB-42CA-4412-B5D8-C853B400604CQ36651592-07F91EAB-858A-4882-B212-3FA3CA4FEF0EQ36805122-2895E516-2176-49AF-97BD-4D5F2B833241Q36946065-B321DB13-A51F-49CD-B2A0-F67A00E95E28Q37095161-5F9CCECD-FF94-466E-880D-93ABFBAF95AEQ37277960-51D59F4C-7AD5-4886-B363-ED28167BF74EQ37522403-20587BF2-0AC0-4FDD-B958-FF5D329C3CEDQ37669397-76D16000-00FD-4525-8CB5-E69F98D9C2E9Q37720797-A6B94325-6D51-4D2E-A6B0-97ADC3F7A098Q38118157-976A35D8-DE94-4341-90C5-141F8E8E79FFQ38126945-5E465D04-61EA-4918-B860-3572E8786BFAQ38148750-A2AE4824-7971-45AC-BE43-EAA4CD190139Q38174491-E6635027-9FC7-4286-8BB9-C7A61A0C1379Q38182499-67B3B6AD-E96D-4EF3-BC00-D368B7FAB2D7Q38200670-37FE5AB7-925E-4E6D-9067-989AE524963FQ38213703-47553A65-146F-4CEC-BDA6-1C4380A7A828Q38258278-02033269-21AD-426E-B031-988C80D18045Q38640778-FA5819AD-51FD-4E90-A6CF-2D9F610C937FQ38823946-908E5ED4-F178-432E-ACA3-BF5814450215Q38836416-823144E0-DD76-461B-9E1B-15A4024054F7Q38960765-D65D693D-D9A1-487D-AFAC-195AFCCF719AQ38969169-46B32C00-2543-42DE-A4CE-34025E28C8FDQ39103371-37949FEC-EDB8-4FA3-8F17-3EED162BB18FQ39329866-11B2D54D-600F-464B-93BC-2D8E32D7408FQ41034635-2F33E265-2DF5-4229-BF13-3F496EDFB6A0Q41849344-0233F4CE-6D1B-40FE-A4F0-90B91F29B2BBQ42376345-0CBDB43C-01F1-4D5E-8E8D-4D3B9A79A3C7
P2860
Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Renal and cardiac effects of D ...... elopment to clinical research.
@en
type
label
Renal and cardiac effects of D ...... elopment to clinical research.
@en
prefLabel
Renal and cardiac effects of D ...... elopment to clinical research.
@en
P2860
P356
P1476
Renal and cardiac effects of D ...... elopment to clinical research.
@en
P2093
Christoph Reichetzeder
Markus L Alter
P2860
P356
10.1159/000339028
P577
2012-08-27T00:00:00Z